Tag:
Corcept Therapeutics
Latest Headlines
Latest Headlines
Corcept tanks as depression drug comes up short in Phase III
Menlo Park, CA's Corcept watched its shares roughly halve Wednesday morning after it pulled the plug on a late-stage trial of an investigational depression treatment.
Corcept execs enjoy raises in wake of drug OK
CEO Joe Belanoff led the pack with an expanded $530,000 salary, up from $481,097. The rare-disease therapy costs up to $20,000 a month.
Rare-disease drugs won't help out-of-work pharma reps
As drugmakers turn their focus to rare-disease drugs, armies of sales reps become unnecessary.
Corcept skyrockets on FDA nod for rare disease drug
U.S. regulators have green-lighted Corcept Therapeutics ' drug Korlym (mifepristone), the first FDA-approved treatment for Cushing's syndrome.
Corcept shares jump on promising PhIII data
Shares of Corcept Therapeutics shot up after the developer announced it had reaped some promising top-line data points from its Phase III study of a new drug for Cushing's syndrome, leaving the Menlo